News – Page 134 – Endpoints News

Ex-Meta scientists launch EvolutionaryScale with $142M seed round, unveiling next-gen AI model for protein design

10 months ago

Can mRNA be harnessed for gene insertion? Moderna's former chief medical officer has $82M to find out

10 months ago

Grail prepares for public debut, and challenges of going independent, after spinoff from Illumina

10 months ago

Korea-based Bridge Biotherapeutics closes Boston office

10 months ago

House committee presses FDA on signs of inconsistent inspections in China and India

10 months ago

Merck KGaA's bet on head and neck cancer drug from Debiopharm ends in Phase 3 failure

10 months ago

Novo Nordisk budgets $4.1B for new US manufacturing site as it abandons plans for Irish build

10 months ago

Phase 3 breast cancer failure leads to staff cuts, stock drop at G1 Therapeutics

10 months ago

Novo reveals more hemophilia A data showing superiority in annualized bleeding rates

10 months ago

Gilead, Viking and Biohaven detail promising preclinical research in obesity and NASH

10 months ago

Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down

10 months ago

UK taps Pfizer over hometown GSK to supply RSV vaccine doses

10 months ago

Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote

10 months ago

Commercial-stage blood cancer biotech files for US dual listing

10 months ago

Schizophrenia biotech LB Pharmaceuticals eyes near-term IPO filing — source

10 months ago

Amylyx, searching for post-ALS future, licenses a GLP-1 drug

10 months ago

Alumis aims for this year’s third-largest biotech IPO as it readies for Phase 3

10 months ago

Altimmune says ‘double G’ drug has even better lean mass preservation data in obesity trial update

10 months ago

Alnylam’s RNAi therapy succeeds in closely-watched Phase 3 heart trial

10 months ago

Fractyl pitches potential of GLP-1 gene therapy, but pushes clinical trials back to 2025

10 months ago

Sarepta's big gene therapy expansion; Inside Iambic's AI cycle; Vertex, Lilly unveil new diabetes data; and more

11 months ago

Argenx wins second FDA approval for Vyvgart in autoimmune nerve disease

11 months ago

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

11 months ago

Three of Vertex’s islet cell therapy patients go insulin-independent

11 months ago

First page Previous page 131 132 133134135 136 137 Next page Last page